CD BioGlyco. news

CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways.

The capacity of cancer cells for aerobic glycolysis is 20–3

CD BioGlyco, a biotechnology company that provides a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, recently released a glyco-engineered mammalian cell expression system to help scientists with their research.

New biotherapeutic glycoproteins, such as recombinant monoclonal antibodies (mAbs), have

CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic.

 The US FDA has approved Pfizer and Moderna`s two vaccines for sale in the US market. The scientific community is still trying